



**Eisai Co., Ltd.**

**4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088 , Japan**

**Phone: 03- 3817-5120**

**Fax: 03- 3811-3077**

**[Please refer to the following notes for product and company profile of Bial]**

Contact:

PR Department  
Eisai Co., Ltd.  
81 - (0)3 - 3817 - 5120

**<Notes to Editors>**

› About ZEBINIX<sup>®</sup>

ZEBINIX<sup>®</sup> (eslicarbazepine acetate) is a novel once a day anti-epileptic drug which is currently being developed by Bial. It exerts its antiepileptic effect by blocking the voltage-gated sodium channels. Data from the three Phase III, multi-centre, randomized, double-blind, placebo-controlled trials with more than 1,000 patients with refractory partial-onset seizures from 23 countries showed its clinical efficacy when used in combination with other anti-epileptic drugs. In addition, ZEBINIX<sup>®</sup> has been demonstrated to improve quality of life and reduce depressive symptoms of patients, during one year open-label extension studies of the above three Phase III trials.

› About Bial – Portela & C<sup>a</sup>, S.A.

Founded in 1924, Bial – Portela & C<sup>a</sup>, S.A. (“Bial”), headquartered in the suburbs of Porto, Portugal, is a research-based and the largest Portuguese pharmaceutical group. Bial makes aggressive investment in R&D, focusing especially on the therapeutic areas of CNS, cardio-vascular diseases, and allergies. Various products developed by Bial are currently available in more than 30 countries worldwide, primarily in Europe, Africa, and Latin America. Its turn over in 2007 was 147 million euros.

For further information about Bial, please visit <http://www.bial.pt>